Cumberland Pharmaceuticals (CPIX) Return on Capital Employed (2011 - 2026)
Cumberland Pharmaceuticals (CPIX) posted Return on Capital Employed of 18.3% for Q1 2026, down 126.86% sequentially from 8.07% in Q4 2025, and down 1137.0% YoY from 1.76% in Q1 2025.
Cumberland Pharmaceuticals (CPIX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Cumberland Pharmaceuticals has reported Return on Capital Employed for 16 years, with the latest figure at 18.3% in Q1 2026.
- Quarterly Return on Capital Employed fell 1137.0% year-over-year to 18.3% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 18.3% (down 1137.0% YoY) and the FY2025 annual result came in at 7.08%, up 659.0% from the prior year.
- Return on Capital Employed fell to 18.3% in Q1 2026 per CPIX's latest filing, from 8.07% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 6.52% in Q2 2023 and troughed at 23.14% in Q3 2024.
- A 5-year average of 12.43% and a median of 11.73% in 2022 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed tumbled 1391 bps in 2024, then soared 1548 bps in 2025.
- Over 5 years, Return on Capital Employed stood at 9.02% in 2022, then sank by 87 bps to 16.83% in 2023, then climbed by 14 bps to 14.44% in 2024, then surged by 44 bps to 8.07% in 2025, then plunged by 127 bps to 18.3% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 18.3%, 8.07%, and 7.66% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Cumberland Pharmaceuticals | 116.56 Mn | 112.69 Mn | - | -30.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30.32% |
| Mar 31, 2026 | -18.30% |
| Dec 31, 2025 | -8.07% |
| Sep 30, 2025 | -7.66% |
| Jun 30, 2025 | -6.66% |
| Mar 31, 2025 | -6.92% |
| Dec 31, 2024 | -14.44% |
| Sep 30, 2024 | -23.14% |
| Jun 30, 2024 | -19.80% |
| Mar 31, 2024 | -17.92% |
| Dec 31, 2023 | -16.83% |
| Sep 30, 2023 | -9.23% |
| Jun 30, 2023 | -6.52% |
| Mar 31, 2023 | -9.08% |
| Dec 31, 2022 | -9.02% |
| Sep 30, 2022 | -11.73% |
| Jun 30, 2022 | -12.87% |
| Mar 31, 2022 | -13.09% |
| Dec 31, 2021 | -11.50% |
| Sep 30, 2021 | -7.21% |